ATP10B Program
Genetic subsets of Parkinson's Disease (e.g., GBA1-associated)
Pre-clinicalActive
Key Facts
Indication
Genetic subsets of Parkinson's Disease (e.g., GBA1-associated)
Phase
Pre-clinical
Status
Active
Company
About EndLyz Therapeutics
EndLyz Therapeutics is a private, pre-clinical biotech emerging from stealth to tackle Parkinson's disease and related dementias by targeting lysosomal dysfunction. The company is advancing a first-in-class portfolio of small molecules against two genetically validated targets, ATP13A2 and ATP10B, with an initial focus on genetic subsets of Parkinson's. Backed by notable venture investors including SV Health Investors, AbbVie Ventures, and Oxford Science Enterprises, EndLyz is positioned to pursue a precision medicine approach with potential expansion into broader sporadic neurodegenerative indications.
View full company profile